Show
Sort by
-
- Journal Article
- A1
- open access
Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy : real-world data from the E2-RADIatE OligoCare cohort
-
- Journal Article
- A1
- open access
Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease : an interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study
-
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy : systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium
-
Radiotherapy treatment volumes for oligorecurrent nodal prostate cancer : a systematic review
-
Oligorecurrent prostate cancer limited to lymph nodes : getting our ducks in a row
-
Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment : a multi-institutional case-control study
-
Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer : a multicenter study
-
Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer : a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy
-
Salvage stereotactic body radiotherapy for isolated lymph node recurrent prostate cancer : single institution series of 94 consecutive patients and 124 lymph nodes
-
Reply from authors re: Vincent Khoo. Is there another bite of the cherry? The case for radical local therapy for oligometastatic disease in prostate cancer. Eur Urol 2016;69:13-4 Oligometastatic prostate cancer: more than just cherry-picking?